Hermesh H, Aizenberg D, Weizman A, Lapidot M, Mayor C, Munitz H
Geha Psychiatric Hospital, Beilinson Medical Center, Petah Tikva, Israel.
Br J Psychiatry. 1992 Aug;161:254-7. doi: 10.1192/bjp.161.2.254.
The occurrence of neuroleptic malignant syndrome (NMS) was studied prospectively in two series of consecutive psychiatric in-patients (n = 223). The first group (n = 120) suffered from schizophrenia and was treated only with haloperidol. The second group (n = 103) was treated with diverse neuroleptics. All patients were on a single antipsychotic agent with no anticholinergic drug as prophylaxis. The incidence of full NMS per admission and first neuroleptic exposure was 5/223 (2.2%). Patients with bipolar affective disorder and those treated with injections were significantly over-represented in the NMS group.
